• 1
    Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 24362441.
  • 2
    Tan J, Lok AS. Update on viral hepatitis: 2006. Curr Opin Gastroenterol 2007; 23: 263267.
  • 3
    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513521.
  • 4
    Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006; 10: 697715.
  • 5
    Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006; 121: 710719.
  • 6
    Younossi ZM, Singer ME, McHutchison JG, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. HEPATOLOGY 1999; 30: 13181324.
  • 7
    Birerdinc A, Younossi ZM. Emerging therapies for hepatitis C virus. Expert Opin Emerg Drugs 2010; doi:10.1517/14728214.2010.502527.
  • 8
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 12921303.
  • 9
    McHutchison JG, Bacon BR, Owens GS. Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care 2007; 13(Suppl. 12): S327S336.
  • 10
    Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. HEPATOLOGY 2007; 45: 806816.
  • 11
    Bacon BR, McHutchison JG. Into the light: strategies for battling hepatitis C. Am J Manag Care 2007; 13(Suppl. 12): S319S326.
  • 12
    Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010; 19: 151159.
  • 13
    Fowell AJ, Nash KL. Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv Ther 2010; 27: 512522.
  • 14
    Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. HEPATOLOGY 2009; 50: 17501755.
  • 15
    Nease DEJr,Maloin JM. Depression screening: a practical strategy. J Fam Pract 2003; 52: 118124.
  • 16
    National Center for Health Statistics, Centers for Disease Control and Prevention. Analytic and reporting guidelines: The National Health and Nutrition Examination Survey (NHANES). Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention; 2005.
  • 17
    U.S. Census Bureau. Percent of people 25 years and over who have completed a bachelor's degree. Published 2003. Accessed August 10, 2010.
  • 18
    Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. HEPATOLOGY 2007; 46: 912921.
  • 19
    Stepanova M, Rafiq N, Younossi Z. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59: 14101415.
  • 20
    Ong JP, Collantes R, Pitts A, Martin L, Sheridan M, Younossi ZM. High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol 2005; 39: 826830.
  • 21
    Kanwal F, Hoang T, Spiegel BM, Goetz M, Gralnek IM, Dominitz JA, et al. Quality of care in chronic hepatitis C virus (HCV) infection. In: Proceedings of the AASLD Liver Meeting (October 27–31, 2006; Boston, MA, USA). Abstract 1296.
  • 22
    Kramer JR, Kanwal F, Mei M, El-Serag H. HCV treatment and SVR: gaps in the face of achieving effectiveness in practice. In: Proceedings of Digestive Disease Week (May 2–5, 2010; New Orleans, LA, USA). Abstract 709.